This startup provides a SaaS platform for genomic analysis of pathogens, enabling biotech companies to quickly identify and characterize microbial threats. Their solution helps accelerate research and development in infectious disease diagnostics and therapeutics.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The global spread of bacterial pathogens and their increasing antibiotic resistance pose a significant threat to international public health. Traditional methods of tracking these pathogens often lack the accuracy, scalability, and connectivity needed for effective surveillance and control.
Solution
Genpax offers IDEM, a high-resolution, automated analysis platform for whole-genome sequencing (WGS) of bacterial pathogens. IDEM enables the integration of healthcare systems, governments, and industry to create a global surveillance ecosystem. The platform delivers accurate, scalable, and connectable WGS analysis, allowing for unambiguous identification of related bacterial strains, detection of re-emergent strains, and generation of fully comparable data across multiple sites. IDEM provides results in near real-time, enabling prompt infection prevention and public health interventions.
Target Audience
Genpax serves healthcare systems, public health organizations, and research institutions involved in infectious disease surveillance and control, as well as organizations in the food industry seeking comprehensive food chain surveillance.
Features
- Advanced, high-definition, natural reference-free analysis of WGS data from bacterial pathogens
- Compatible with any Illumina sequencer
- Automated Quality Control (QC) for all isolates
- User-friendly and interactive view of the relationships between isolates
- Continuous monitoring of transmissions over time
- Species confirmation and key AMR and virulence-associated gene detection
- Custom reporting available
- Cloud-based platform, removing the need for local IT infrastructure and bioinformatics expertise